Prevention of Vaginal Cellulitis or Vaginal Cuff Abscess After Laparoscopic Hysterectomy
Primary Purpose
Hysterectomy, Cellulitis, Vaginosis
Status
Unknown status
Phase
Not Applicable
Locations
Colombia
Study Type
Interventional
Intervention
cephalosporin + Metronidazole Vaginal
cephalosporin + Placebos
Sponsored by
About this trial
This is an interventional prevention trial for Hysterectomy
Eligibility Criteria
Inclusion Criteria:
- Patients between 18 and 55 years old scheduled for laparoscopic hysterectomy for benign pathology in the two centers linked to the study (Clínica del Prado and Pereira community clinic), who have been informed of their participation in the study and who have signed informed consent.
- Patients who are able to communicate by telephone and answer questions
Exclusion Criteria:
- Patients who are participating in another study of antibiotic treatment.
- Patients who have a known allergy to imidazole medications.
- Patients with current diagnosis of bacterial vaginosis.
- Patients with current treatment or 30 days prior to surgery for bacterial vaginosis or antibiotic treatment for another pathology.
- Patients who do not reside in Medellín or in its nearby municipalities and can not attend the scheduled evaluation.
Sites / Locations
- Clinica del prado
- Clínica comfamiliar pereira
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
cephalosporin + Metronidazole
cephalosporin + placebo
Arm Description
In this arm, patients randomly selected, will receive cephalosporin in doses of 2 grams administered intravenously before surgery. metronidazole vaginal ovules of 500mg twice a day for 5 days after surgery
In this arm, patients randomly selected, will receive cephalosporin in doses of 2 grams administered intravenously before surgery. placebo vaginal ovules twice a day for 5 days after surgery
Outcomes
Primary Outcome Measures
Incidence of cellulitis and vaginal cuff abscess
Secondary Outcome Measures
percentage of patients who will undergo laparoscopic hysterectomy have bacterial vaginosis at the time of the procedure.
need to perform additional procedures as part of the treatment in each of the groups.
percentage of patients who comply with the prescribed treatment completely.
Full Information
NCT ID
NCT03917134
First Posted
April 3, 2019
Last Updated
April 15, 2019
Sponsor
CES University
Collaborators
Lafrancol S.A., Prolab S.A, Clínica del prado, Clínica comfamiliar pereira
1. Study Identification
Unique Protocol Identification Number
NCT03917134
Brief Title
Prevention of Vaginal Cellulitis or Vaginal Cuff Abscess After Laparoscopic Hysterectomy
Official Title
Efficacy of the Use of Metronidazole After Laparoscopic Hysterectomy for the Prevention of Vaginal Cellulitis or Vaginal Cuff Abscess. Multicentric Triple-blind Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
April 2019
Overall Recruitment Status
Unknown status
Study Start Date
May 1, 2019 (Anticipated)
Primary Completion Date
January 30, 2020 (Anticipated)
Study Completion Date
January 30, 2020 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
CES University
Collaborators
Lafrancol S.A., Prolab S.A, Clínica del prado, Clínica comfamiliar pereira
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Operative site infection remains the most common complication after performing a gynecological procedure, and has a great implication in the morbidity and mortality of patients. Gynecological procedures, including laparoscopic hysterectomy, represent a unique challenge due to the amount of microorganisms found at the skin level of the vagina or the endocervix.
However, there is no clear evidence that the complication decreases with the use of postoperative antibiotics.
With the completion of this study, a multicentre triple-blind controlled randomized controlled trial is intended to determine the behavior of the application of this intervention.
Patients who attend an outpatient clinic with benign pathology will be selected, in which indication of laparoscopic hysterectomy, consents are completed and research content is widely explained. Prior to surgery, the sample is taken for a gram of vaginal discharge and in the post-surgical phase delivery of the medication will be performed. Follow-up will be carried out by surgical control and by telephone.
The investigator intend to find that with the prophylaxis not only of presurgical cephalosporin, but with the formulation of metronidazole ovules in the postoperative, the incidence of laparoscopic post-hysterectomy vaginal abscess and cellulitis of cuff is reduced.
Detailed Description
The development of the project will be carried out in the facilities of the Prado clinic in the city of Medellín and the Comfamily Clinic in the city of Pereira. Initially to the participants who attend by external consultation for assessment by the laparoscopic gynecology group that are candidates to perform a laparoscopic hysterectomy, they will be given general information about the research in development and its possible participation. Later on the day of surgery in the preparation room and before receiving any medication, The assigned investigator as assistant to the surgery will explain in detail the protocol of the investigation, the commitments acquired by the participant and the possibilities of withdrawal of the same, you will obtain the signature and trace of the informed consent. With the aim of not delaying the 7 am surgical program, a weekly resident will be assigned to inform and fill out the forms of the first patients scheduled for hysterectomy.
Advance by means of a table of random numbers generated in EPIDAT and that is hidden for the researcher. Participants will be assigned to one of the 2 groups, the intervention group will receive the treatment scheme with metronidazole 500mg ovules every 12 hours for 5 days and the control group will receive a placebo.
After this in the surgery room and with the participants under general anesthesia, the sample will be taken for gram of vaginal discharge, previous marking of the plate, with the initials of names and surnames and the patient's identification number, With the use of a speculum and applicator the sample will be taken in the sack bottoms or vaginal walls, which will be sent to the Prolab laboratory in the city of Medellín and the laboratory of the Comfamily clinic in the city of Pereira. for its processing, standardization will be made prior to reading it with the staff of both laboratories.
For the diagnosis of bacterial vaginosis, the Nugent criteria will be used. In this method, the morphotypes corresponding to large Gram-positive bacilli, small Gram-negative bacilli and curved variable Gram bacilli are quantified. And a value is assigned according to the findings. The interpretation of the results is numerical based on the score obtained by adding the crosses of the morphotypes of the bacteria present in the vaginal discharge: 7 or more points are diagnostic of bacterial vaginosis, from 4 to 6 points is considered intermediate and from 0 to 3 is considered normal.
At the end of the surgical procedure, the investigator will complete the completion of Annex 1, will go to the pharmaceutical service where he will request the corresponding product to the patient. The pharmacy staff will verify the assigned number in the randomization table and deliver the medication and the resident will take it to the recovery room with its respective formula.
The assigned investigator will conduct a telephone interview 7 days after the procedure to assess the post-surgical evolution, will be questioned about the presence of symptoms that may be related to an infectious process. Between 10-15 days of the surgical procedure, the gynecologist will perform the post-surgical review in an outpatient clinic to assess the evolution of the patient and re-evaluate the result of the pathology. The Gram result of vaginal discharge, the pathology and the evolution note made by the surgeon will be reviewed with the aim of detecting any diagnosed complication. Finally, 30 days after the procedure, the last telephone follow-up will be performed to detect the presence of any infection. of the operative site.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hysterectomy, Cellulitis, Vaginosis, Abscess, Cuff
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
600 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
cephalosporin + Metronidazole
Arm Type
Experimental
Arm Description
In this arm, patients randomly selected, will receive cephalosporin in doses of 2 grams administered intravenously before surgery. metronidazole vaginal ovules of 500mg twice a day for 5 days after surgery
Arm Title
cephalosporin + placebo
Arm Type
Placebo Comparator
Arm Description
In this arm, patients randomly selected, will receive cephalosporin in doses of 2 grams administered intravenously before surgery. placebo vaginal ovules twice a day for 5 days after surgery
Intervention Type
Drug
Intervention Name(s)
cephalosporin + Metronidazole Vaginal
Intervention Description
administration of cephalosporin in doses of 2 grams administered intravenously before surgery and metronidazole vaginal ovules 500mg twice a day for 5 days after performing laparoscopic hysterectomy
Intervention Type
Drug
Intervention Name(s)
cephalosporin + Placebos
Intervention Description
administration of cephalosporin in doses of 2 grams administered intravenously before surgery and vaginal ovules of placebo twice a day for 5 days after performing laparoscopic hysterectomy
Primary Outcome Measure Information:
Title
Incidence of cellulitis and vaginal cuff abscess
Time Frame
30 days
Secondary Outcome Measure Information:
Title
percentage of patients who will undergo laparoscopic hysterectomy have bacterial vaginosis at the time of the procedure.
Time Frame
15 days
Title
need to perform additional procedures as part of the treatment in each of the groups.
Time Frame
30 days
Title
percentage of patients who comply with the prescribed treatment completely.
Time Frame
15 days
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients between 18 and 55 years old scheduled for laparoscopic hysterectomy for benign pathology in the two centers linked to the study (Clínica del Prado and Pereira community clinic), who have been informed of their participation in the study and who have signed informed consent.
Patients who are able to communicate by telephone and answer questions
Exclusion Criteria:
Patients who are participating in another study of antibiotic treatment.
Patients who have a known allergy to imidazole medications.
Patients with current diagnosis of bacterial vaginosis.
Patients with current treatment or 30 days prior to surgery for bacterial vaginosis or antibiotic treatment for another pathology.
Patients who do not reside in Medellín or in its nearby municipalities and can not attend the scheduled evaluation.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
CLAUDIA LOPEZ, Gynecologist
Phone
3104365060
Email
cclopez04@yahoo.com
First Name & Middle Initial & Last Name or Official Title & Degree
VICTOR H VALENCIA
Phone
3128313718
Email
vicval87@hotmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
CLAUDIA LOPEZ, Gynecologist
Organizational Affiliation
CES University - Clínica del prado
Official's Role
Principal Investigator
Facility Information:
Facility Name
Clinica del prado
City
Medellín
Country
Colombia
Facility Contact:
Phone
5745765700
First Name & Middle Initial & Last Name & Degree
CLAUDIA LOPEZ, Gynecologist
Facility Name
Clínica comfamiliar pereira
City
Pereira
Country
Colombia
Facility Contact:
Phone
5763135700
First Name & Middle Initial & Last Name & Degree
JUAN D VILLEGAS, Gynecologist
12. IPD Sharing Statement
Plan to Share IPD
Yes
Citations:
PubMed Identifier
19384149
Citation
ACOG practice bulletin No. 104: antibiotic prophylaxis for gynecologic procedures. Obstet Gynecol. 2009 May;113(5):1180-1189. doi: 10.1097/AOG.0b013e3181a6d011. No abstract available.
Results Reference
result
PubMed Identifier
19104364
Citation
Lowe NK, Neal JL, Ryan-Wenger NA. Accuracy of the clinical diagnosis of vaginitis compared with a DNA probe laboratory standard. Obstet Gynecol. 2009 Jan;113(1):89-95. doi: 10.1097/AOG.0b013e3181909f63.
Results Reference
result
PubMed Identifier
7361218
Citation
Brachman PS, Dan BB, Haley RW, Hooton TM, Garner JS, Allen JR. Nosocomial surgical infections: incidence and cost. Surg Clin North Am. 1980 Feb;60(1):15-25. doi: 10.1016/s0039-6109(16)42030-x.
Results Reference
result
PubMed Identifier
8906013
Citation
Persson E, Bergstrom M, Larsson PG, Moberg P, Platz-Christensen JJ, Schedvins K, Wolner-Hanssen P. Infections after hysterectomy. A prospective nation-wide Swedish study. The Study Group on Infectious Diseases in Obstetrics and Gynecology within the Swedish Society of Obstetrics and Gynecology. Acta Obstet Gynecol Scand. 1996 Sep;75(8):757-61. doi: 10.3109/00016349609065742.
Results Reference
result
PubMed Identifier
19588379
Citation
Oduyebo OO, Anorlu RI, Ogunsola FT. The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD006055. doi: 10.1002/14651858.CD006055.pub2.
Results Reference
result
PubMed Identifier
10028110
Citation
Joesoef MR, Schmid GP, Hillier SL. Bacterial vaginosis: review of treatment options and potential clinical indications for therapy. Clin Infect Dis. 1999 Jan;28 Suppl 1:S57-65. doi: 10.1086/514725.
Results Reference
result
PubMed Identifier
12625969
Citation
Larsson PG, Carlsson B. Does pre- and postoperative metronidazole treatment lower vaginal cuff infection rate after abdominal hysterectomy among women with bacterial vaginosis? Infect Dis Obstet Gynecol. 2002;10(3):133-40. doi: 10.1155/S1064744902000133.
Results Reference
result
PubMed Identifier
1504154
Citation
Larsson PG. Treatment of bacterial vaginosis. Int J STD AIDS. 1992 Jul-Aug;3(4):239-47. doi: 10.1177/095646249200300402. No abstract available.
Results Reference
result
PubMed Identifier
21944221
Citation
McElligott KA, Havrilesky LJ, Myers ER. Preoperative screening strategies for bacterial vaginosis prior to elective hysterectomy: a cost comparison study. Am J Obstet Gynecol. 2011 Nov;205(5):500.e1-7. doi: 10.1016/j.ajog.2011.07.012. Epub 2011 Jul 20.
Results Reference
result
PubMed Identifier
15902186
Citation
Schey D, Salom EM, Papadia A, Penalver M. Extensive fever workup produces low yield in determining infectious etiology. Am J Obstet Gynecol. 2005 May;192(5):1729-34. doi: 10.1016/j.ajog.2004.11.049.
Results Reference
result
PubMed Identifier
11425832
Citation
Makinen J, Johansson J, Tomas C, Tomas E, Heinonen PK, Laatikainen T, Kauko M, Heikkinen AM, Sjoberg J. Morbidity of 10 110 hysterectomies by type of approach. Hum Reprod. 2001 Jul;16(7):1473-8. doi: 10.1093/humrep/16.7.1473.
Results Reference
result
PubMed Identifier
18954757
Citation
Faro C, Faro S. Postoperative pelvic infections. Infect Dis Clin North Am. 2008 Dec;22(4):653-663. doi: 10.1016/j.idc.2008.05.005.
Results Reference
result
PubMed Identifier
23770467
Citation
Lake AG, McPencow AM, Dick-Biascoechea MA, Martin DK, Erekson EA. Surgical site infection after hysterectomy. Am J Obstet Gynecol. 2013 Nov;209(5):490.e1-9. doi: 10.1016/j.ajog.2013.06.018. Epub 2013 Jun 13.
Results Reference
result
PubMed Identifier
12048413
Citation
Tamussino K. Postoperative infection. Clin Obstet Gynecol. 2002 Jun;45(2):562-73. doi: 10.1097/00003081-200206000-00026. No abstract available.
Results Reference
result
PubMed Identifier
23327981
Citation
Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, Fish DN, Napolitano LM, Sawyer RG, Slain D, Steinberg JP, Weinstein RA; American Society of Health-System Pharmacists; Infectious Disease Society of America; Surgical Infection Society; Society for Healthcare Epidemiology of America. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 2013 Feb 1;70(3):195-283. doi: 10.2146/ajhp120568. No abstract available.
Results Reference
result
PubMed Identifier
23963423
Citation
American College of Obstetricians and Gynecologists Women's Health Care Physicians; Committee on Gynecologic Practice. Committee Opinion No. 571: Solutions for surgical preparation of the vagina. Obstet Gynecol. 2013 Sep;122(3):718-20. doi: 10.1097/01.AOG.0000433982.36184.95.
Results Reference
result
PubMed Identifier
10371477
Citation
Lin L, Song J, Kimber N, Shott S, Tangora J, Aroutcheva A, Mazees MB, Wells A, Cohen A, Faro S. The role of bacterial vaginosis in infection after major gynecologic surgery. Infect Dis Obstet Gynecol. 1999;7(3):169-74. doi: 10.1002/(SICI)1098-0997(1999)7:33.0.CO;2-J.
Results Reference
result
PubMed Identifier
23659989
Citation
Kenyon C, Colebunders R, Crucitti T. The global epidemiology of bacterial vaginosis: a systematic review. Am J Obstet Gynecol. 2013 Dec;209(6):505-23. doi: 10.1016/j.ajog.2013.05.006. Epub 2013 May 6.
Results Reference
result
PubMed Identifier
17197596
Citation
Allsworth JE, Peipert JF. Prevalence of bacterial vaginosis: 2001-2004 National Health and Nutrition Examination Survey data. Obstet Gynecol. 2007 Jan;109(1):114-20. doi: 10.1097/01.AOG.0000247627.84791.91.
Results Reference
result
PubMed Identifier
17621244
Citation
Koumans EH, Sternberg M, Bruce C, McQuillan G, Kendrick J, Sutton M, Markowitz LE. The prevalence of bacterial vaginosis in the United States, 2001-2004; associations with symptoms, sexual behaviors, and reproductive health. Sex Transm Dis. 2007 Nov;34(11):864-9. doi: 10.1097/OLQ.0b013e318074e565.
Results Reference
result
PubMed Identifier
18947329
Citation
Fethers KA, Fairley CK, Hocking JS, Gurrin LC, Bradshaw CS. Sexual risk factors and bacterial vaginosis: a systematic review and meta-analysis. Clin Infect Dis. 2008 Dec 1;47(11):1426-35. doi: 10.1086/592974.
Results Reference
result
PubMed Identifier
25589333
Citation
Esber A, Vicetti Miguel RD, Cherpes TL, Klebanoff MA, Gallo MF, Turner AN. Risk of Bacterial Vaginosis Among Women With Herpes Simplex Virus Type 2 Infection: A Systematic Review and Meta-analysis. J Infect Dis. 2015 Jul 1;212(1):8-17. doi: 10.1093/infdis/jiv017. Epub 2015 Jan 14.
Results Reference
result
PubMed Identifier
11576584
Citation
Jamieson DJ, Duerr A, Klein RS, Paramsothy P, Brown W, Cu-Uvin S, Rompalo A, Sobel J. Longitudinal analysis of bacterial vaginosis: findings from the HIV epidemiology research study. Obstet Gynecol. 2001 Oct;98(4):656-63. doi: 10.1016/s0029-7844(01)01525-3.
Results Reference
result
PubMed Identifier
14672465
Citation
Yen S, Shafer MA, Moncada J, Campbell CJ, Flinn SD, Boyer CB. Bacterial vaginosis in sexually experienced and non-sexually experienced young women entering the military. Obstet Gynecol. 2003 Nov;102(5 Pt 1):927-33. doi: 10.1016/s0029-7844(03)00858-5.
Results Reference
result
PubMed Identifier
15291998
Citation
Klebanoff MA, Schwebke JR, Zhang J, Nansel TR, Yu KF, Andrews WW. Vulvovaginal symptoms in women with bacterial vaginosis. Obstet Gynecol. 2004 Aug;104(2):267-72. doi: 10.1097/01.AOG.0000134783.98382.b0.
Results Reference
result
PubMed Identifier
9065140
Citation
Goldenberg RL, Klebanoff MA, Nugent R, Krohn MA, Hillier S, Andrews WW. Bacterial colonization of the vagina during pregnancy in four ethnic groups. Vaginal Infections and Prematurity Study Group. Am J Obstet Gynecol. 1996 May;174(5):1618-21. doi: 10.1016/s0002-9378(96)70617-8.
Results Reference
result
PubMed Identifier
6600371
Citation
Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med. 1983 Jan;74(1):14-22. doi: 10.1016/0002-9343(83)91112-9.
Results Reference
result
PubMed Identifier
26042815
Citation
Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015 Jun 5;64(RR-03):1-137. Erratum In: MMWR Recomm Rep. 2015 Aug 28;64(33):924.
Results Reference
result
PubMed Identifier
15118630
Citation
Landers DV, Wiesenfeld HC, Heine RP, Krohn MA, Hillier SL. Predictive value of the clinical diagnosis of lower genital tract infection in women. Am J Obstet Gynecol. 2004 Apr;190(4):1004-10. doi: 10.1016/j.ajog.2004.02.015.
Results Reference
result
PubMed Identifier
22975936
Citation
Al-Banna NA, Pavlovic D, Grundling M, Zhou J, Kelly M, Whynot S, Hung O, Johnston B, Issekutz TB, Kern H, Cerny V, Lehmann Ch. Impact of antibiotics on the microcirculation in local and systemic inflammation. Clin Hemorheol Microcirc. 2013;53(1-2):155-69. doi: 10.3233/CH-2012-1583.
Results Reference
result
PubMed Identifier
22529484
Citation
Thulkar J, Kriplani A, Agarwal N. A comparative study of oral single dose of metronidazole, tinidazole, secnidazole and ornidazole in bacterial vaginosis. Indian J Pharmacol. 2012 Mar;44(2):243-5. doi: 10.4103/0253-7613.93859.
Results Reference
result
PubMed Identifier
16145097
Citation
Austin MN, Beigi RH, Meyn LA, Hillier SL. Microbiologic response to treatment of bacterial vaginosis with topical clindamycin or metronidazole. J Clin Microbiol. 2005 Sep;43(9):4492-7. doi: 10.1128/JCM.43.9.4492-4497.2005.
Results Reference
result
PubMed Identifier
1535108
Citation
Lugo-Miro VI, Green M, Mazur L. Comparison of different metronidazole therapeutic regimens for bacterial vaginosis. A meta-analysis. JAMA. 1992 Jul 1;268(1):92-5.
Results Reference
result
Learn more about this trial
Prevention of Vaginal Cellulitis or Vaginal Cuff Abscess After Laparoscopic Hysterectomy
We'll reach out to this number within 24 hrs